Second, data from patients with hotspot KRAS+/TP53-, KRAS-/TP53+, and KRAS-/TP53- cancer were not available for our analysis of patients with metastatic KRAS+/TP53+ mutant cancer, which limited our ability to reach conclusions from data comparison among these four groups of patients. This evidence concerns the gene KRAS and cancer.